BridgeBio Pharma Income After Taxes 2018-2024 | BBIO

BridgeBio Pharma income after taxes from 2018 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.

BridgeBio Pharma Income After Taxes 2018-2024 | BBIO

BridgeBio Pharma income after taxes from 2018 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19B
Dr Reddy's Laboratories (RDY)$12B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.1B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$434M
Personalis (PSNL)$261M
Assembly Biosciences (ASMB)$98M
Sol-Gel Technologies (SLGL)$12M
Evoke Pharma (EVOK)$7M
Teligent (TLGT)$0M